Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, an...

Full description

Bibliographic Details
Main Authors: Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim
Format: Article
Language:English
Published: Korean Association for the Study of the Liver 2021-07-01
Series:Clinical and Molecular Hepatology
Subjects:
entecavir
tenofovir
hepatitis b
carcinoma, hepatocellular
efficacy
outcome
Online Access:http://e-cmh.org/upload/pdf/cmh-2021-0179.pdf

Internet

http://e-cmh.org/upload/pdf/cmh-2021-0179.pdf

Similar Items